Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 9/20 | 0.77 |
| ▸ | PPARG | P37231 | 5/20 | 0.77 |
| ▸ | FABP2 | P12104 | 2/20 | 0.77 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.77 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.67 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.67 |
| ▸ | MAPT | P10636 | 3/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | MEN1 | O00255 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | HPGD | P15428 | 2/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 2/20 | 0.67 |
| ▸ | HTR2A | P28223 | 2/20 | 0.67 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.67 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.67 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.67 |
| ▸ | USP2 | O75604 | 2/20 | 0.67 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL135713 | 0.91 | PPARA (0.72) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| SCHEMBL13983694 | 0.87 | PPARA (0.59) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| Fenofibric Acid SCHEMBL16377 | 0.87 | PPARA (1.00) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| SCHEMBL13984052 | 0.87 | PPARA (0.77) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| SCHEMBL11537290 | 0.86 | PPARA (0.66) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| Fenofibric Acid SCHEMBL28478335 | 0.85 | PPARA (0.97) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| SCHEMBL16577214 | 0.85 | PPARA (0.74) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| SCHEMBL11161555 | 0.85 | PPARA (0.74) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| Fenofibric Acid SCHEMBL10967778 | 0.85 | PPARA (0.97) | PPARAPPARGFABP2SLC22A12CYP1A2 | |
| SCHEMBL12634744 | 0.85 | PPARA (0.74) | PPARAPPARGFABP2SLC22A12CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110288331-A1 | PROCESS FOR THE PREPARATION OF CHOLINE SALT OF FENOFIBRIC ACID AND ITS NOVEL POLYMORPH | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2011-11-24 | — | — | US | disclosed |
| US-20110288331-A1 | PROCESS FOR THE PREPARATION OF CHOLINE SALT OF FENOFIBRIC ACID AND ITS NOVEL POLYMORPH | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2011-11-24 | — | — | US | disclosed |
| US-20110160225-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160225-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110160225-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2011-06-30 | — | — | US | disclosed |
| US-20110021471-A1 | REDUCING Abeta42 LEVELS AND Abeta AGGREGATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2011-01-27 | — | — | US | disclosed |
| US-20110021471-A1 | REDUCING Abeta42 LEVELS AND Abeta AGGREGATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2011-01-27 | — | — | US | disclosed |
| WO-2010086700-A2 | AN IMPROVED PROCESS FOR THE PREPARATION OF CHOLINE SALT OF FENOFIBRIC ACID AND ITS NOVEL POLYMORPH | ALEMBIC LIMITED (IN) | 2010-08-05 | — | — | WO | disclosed |
| WO-2009059239-A2 | REDUCING Aβ42 LEVELS AND Aβ AGGREGATION | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH (US) | 2009-05-07 | — | — | WO | disclosed |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC. (US) | 2009-02-26 | — | — | US | disclosed |
| WO-2008157537-A2 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC (US) | 2008-12-24 | — | — | WO | disclosed |
| WO-2008157537-A2 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | IRONWOOD PHARMACEUTICALS, INC (US) | 2008-12-24 | — | — | WO | disclosed |
| US-5310757-A | Hypolipemic, hypocholesterol | PANMEDICA (FR) | 1994-05-10 | — | — | US | disclosed |
| US-4515809-A | ANTICHOLESTEROL | ALFA FARMACEUTICI S.P.A. (IT) | 1985-05-07 | — | — | US | disclosed |
| US-4378373-A | Derivatives of benzoylphenoxyalkanoic acids having normolipemizing activity | ALFA FARMACEUTICI S.P.A. (IT) | 1983-03-29 | — | — | US | disclosed |
| EP-0007648-B1 | NEW ACYLUREAS WITH PHARMACEUTICAL ACTIVITY, THE PROCESS FOR THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS WHICH CONTAIN THEM | Investigacion Tecnica Y Aplicada, S.A. (ES) | 1982-08-11 | — | — | EP | disclosed |
| US-4296125-A | Derivatives of benzoylphenoxyalkanoic acids having normolipemizing activity | ALPHA FARMACEUTICI S.P.A. (IT) | 1981-10-20 | — | — | US | disclosed |
| US-4146728-A | Esters of 2-[4-(4-chlorobenzoyl)-phenoxy-2-methyl-propionic acid with bis-(hydroxyalkylthio)-alkanes | LABORATOIRE L. LAFON (FR) | 1979-03-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021471-A1 | REDUCING Abeta42 LEVELS AND Abeta AGGREGATION | APP, BACE1, GAP43 | PPARA 2196/4885PPARG 3466/4885FABP2 647/4885 |
| US-20110160225-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | LIPC, PNLIP, LIPA | PPARA 93/4885PPARG 104/4885FABP2 51/4885 |
| US-20110288331-A1 | PROCESS FOR THE PREPARATION OF CHOLINE SALT OF FENOFIBRIC ACID AND ITS NOVEL POLYMORPH | CHKB, HMGCR, CEL | PPARA 58/4885PPARG 357/4885FABP2 798/4885 |
| US-20090054450-A1 | COMPOSITIONS AND METHODS OF USE FOR TREATING OR PREVENTING LIPID RELATED DISORDERS | LIPC, PNLIP, LIPA | PPARA 93/4885PPARG 104/4885FABP2 51/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.